DM
CBAY

Deerfield Management’s Cymabay Therapeutics CBAY Stock Holding History

Deerfield Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,343,181
Closed -$10.6M – 107
2018
Q4 		$10.6M Hold
1,343,181
– – 0.42% 58
2018
Q3 		$14.9M Hold
1,343,181
– – 0.53% 59
2018
Q2 		$18M Buy
1,343,181
+130,000
+11% +$1.63M 0.63% 59
2018
Q1 		$15.8M Buy
+1,213,181
New +$15.1M 0.55% 66
2014
Q4 		– Sell
-513,206
Closed -$3.51M – 134
2014
Q3 		$3.51M Buy
+513,206
New +$3.15M 0.13% 104

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Deerfield Management's CBAY Position: Q1 2019 in Review

Deerfield Management sold out of Cymabay Therapeutics (CBAY) in Q1 2019, closing a stake of 1,343,181 shares — an estimated $10.6M sold.

Deerfield Management first reported a position in CBAY in Q3 2014 and held it in 5 quarters. The position peaked at $18M in Q2 2018. 142 funds tracked by Wall St. Rank hold CBAY as of Q1 2019.

  • Deerfield Management reported no remaining Cymabay Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Deerfield Management sold 1,343,181 Cymabay Therapeutics shares in Q1 2019, an estimated $10.6M.
  • Deerfield Management first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 5 quarters.
  • Deerfield Management's Cymabay Therapeutics position peaked at $18M in Q2 2018.
  • 142 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2019.

Based on Deerfield Management's 13F filing for Q1 2019, filed 15 May 2019.